Medical Pharmacology Question Bank

Chapter 2: Pharmacokinetics — Module 2: Volume of Distribution, Protein Binding, and Compartments
Tier: Tier 2 — Conceptual Understanding

1. A 78-year-old man with moderate dementia, heart failure (LVEF 28%), and stage 3b CKD (eGFR 32 mL/min/1.73m²) requires digoxin for rate control of atrial fibrillation. His estimated lean body weight is 52 kg. Digoxin distributes extensively into skeletal muscle and cardiac tissue with a volume of distribution of approximately 7 L/kg in healthy adults. Using the loading dose formula LD = Target Css × Vd (IV administration), and targeting a steady-state trough concentration of 0.8 ng/mL (0.8 mcg/L) for AF rate control, calculate the appropriate loading dose and explain why lean body weight — not actual body weight or ideal body weight — must be used for this calculation.

A) LD = 0.8 mcg/L × (7 L/kg × 70 kg) = 0.8 × 490 = 392 mcg 400 mcg IV; actual body weight is used because digoxin distributes into all tissues including adipose tissue; obese patients should receive proportionally larger loading doses than lean patients
B) LD = 0.8 mcg/L × (7 L/kg × 52 kg) = 0.8 × 364 = 291 mcg 300 mcg IV; lean body weight is used because digoxin distributes primarily into skeletal muscle (not adipose tissue) — its large Vd reflects binding to myosin in cardiac and skeletal muscle; adipose tissue, which contains minimal muscle protein, does not contribute meaningfully to digoxin distribution volume; using actual or ideal body weight in obese or sarcopenic patients would over- or under-estimate Vd respectively; in this 78-year-old with likely sarcopenia and low muscle mass, the lean body weight of 52 kg most accurately reflects the metabolically active tissue mass into which digoxin distributes, yielding an estimated Vd of approximately 364 L and a loading dose of approximately 291 mcg IV (typically rounded to 250–500 mcg based on clinical context and renal function)
C) LD = 0.8 mcg/L × (7 L/kg × 52 kg) / 0.65 = 448 mcg 450 mcg; lean body weight is adjusted by the oral bioavailability factor of 0.65 even for IV administration because bioavailability affects the volume into which digoxin distributes
D) Loading doses for digoxin are always fixed at 0.5 mg (500 mcg) regardless of body weight, age, or renal function — individual pharmacokinetic calculations are unnecessary because digoxin loading doses are population-standardized values based on clinical trial data that cannot be improved by individual body composition adjustment
E) LD = Target Css / Vd per kg = 0.8 / 7 = 0.11 mcg/kg; this per-kg ratio is then administered as a fixed concentration regardless of patient weight — the loading dose formula does not require weight-based calculation because Vd is expressed per unit body weight

ANSWER: B

Rationale:

This question integrates loading dose calculation with the pharmacokinetically important distinction of which body weight measure appropriately reflects drug distribution volume. Loading dose formula: LD = Target Css × Vd. For IV administration, F = 1.0, so no bioavailability correction is needed. The critical question is which body weight measure to apply to the Vd constant of 7 L/kg. Digoxin's large Vd (5–10 L/kg, approximately 500–700 L in standard reference adults) reflects its avid binding to Na/K-ATPase, particularly in cardiac muscle and skeletal muscle. Adipose tissue contains little Na/K-ATPase and contributes minimally to digoxin distribution. Therefore, the effective distribution volume scales with lean (muscle-containing) body mass, not total body weight: in obese patients, using total body weight overestimates Vd and produces supratherapeutic loading doses; in sarcopenic elderly patients (like this 78-year-old with HFrEF and CKD), even lean body weight may overestimate functional muscle mass. Using lean body weight of 52 kg: estimated Vd = 7 L/kg × 52 kg = 364 L. LD = 0.8 mcg/L × 364 L = 291 mcg 250–300 mcg IV. In clinical practice, digoxin loading is often given in divided doses (e.g., 250 mcg now, then reassess) particularly in elderly patients with CKD (where reduced renal clearance prolongs digoxin half-life and makes toxicity more likely with large single loading doses). This patient's reduced eGFR (32 mL/min/1.73m²) will also dramatically prolong digoxin's elimination half-life (from normal 36–48 hours to potentially 80–100+ hours), requiring extended dosing intervals for maintenance. Option A incorrectly uses 70 kg standard weight — this elderly patient weighs considerably less, and adipose tissue does not contribute to digoxin distribution. Option C incorrectly applies bioavailability (F = 0.65 for oral digoxin) to an IV loading dose — IV administration has F = 1.0. Option D is incorrect — digoxin loading doses must be individualized based on Vd (lean body weight), target concentration, and renal function. Option E performs an incorrect mathematical inversion of the loading dose formula.

2. A researcher compares the pharmacokinetics of two drugs: Drug A (Vd = 4 L, plasma protein binding 98%, fu = 0.02; fu is fraction unbound ) and Drug B (Vd = 400 L, plasma protein binding 40%, fu = 0.60). Both drugs have the same total plasma concentration of 10 mg/L at steady state. Which of the following correctly calculates the free (unbound) drug concentration for each drug and identifies which drug has higher free drug exposure at the same total plasma concentration, and which is more likely to be removed by hemodialysis in overdose?

A) Drug A free concentration = 10 × 0.02 = 0.2 mg/L; Drug B free concentration = 10 × 0.60 = 6.0 mg/L; Drug B has 30-fold higher free drug concentration at the same total plasma concentration; Drug A is more likely to be dialyzable because its smaller Vd (4 L) means most drug resides in the plasma compartment — despite high protein binding limiting the free fraction available for dialysis at any instant, the small Vd ensures the overall drug burden is accessible to the dialyzer; Drug B with Vd = 400 L would have 96.8% of total body drug in peripheral tissues at steady state, making hemodialysis pharmacokinetically ineffective regardless of its lower protein binding
B) Drug A free concentration = 10 / 0.02 = 500 mg/L; Drug B free concentration = 10 / 0.60 = 16.7 mg/L; Drug A has higher free drug exposure; Drug B is more dialyzable because its lower protein binding allows more free drug to cross the dialysis membrane per unit time
C) Both drugs have the same free drug concentration because total plasma concentration is the same — protein binding does not affect the pharmacologically active free drug concentration at steady state; drug B is more dialyzable because its higher fu means more drug crosses the dialysis membrane
D) Drug A free concentration = 10 × 0.98 = 9.8 mg/L (bound fraction); Drug B free concentration = 10 × 0.40 = 4.0 mg/L (bound fraction); Drug A has higher pharmacological activity because bound drug is the active fraction; neither drug is dialyzable because protein-bound drugs are retained in the vasculature during dialysis
E) Drug A free concentration = 10 × 0.02 = 0.2 mg/L; Drug B free concentration = 10 × 0.60 = 6.0 mg/L; Drug B has higher free drug concentration; Drug B is more dialyzable because its large Vd means most drug resides in the plasma compartment where it is accessible to the dialysis membrane

ANSWER: A

Rationale:

This question integrates free drug calculation, pharmacological activity, and dialyzability prediction — three related but distinct applications of protein binding pharmacokinetics. Free drug concentration calculation: Cfree = Ctotal × fu. Drug A: Cfree = 10 mg/L × 0.02 = 0.2 mg/L. Drug B: Cfree = 10 mg/L × 0.60 = 6.0 mg/L. At the same total plasma concentration, Drug B has 30-fold higher free drug concentration — meaning substantially greater pharmacological activity (receptor binding), more drug available for hepatic metabolism and renal filtration, and potentially greater adverse effect risk. This illustrates why total plasma concentration can be misleading when comparing drugs with different protein binding: the same measured total concentration produces dramatically different pharmacological exposures depending on fu. Dialyzability comparison: Drug A (Vd = 4 L) — a Vd of 4 L is approximately equal to plasma volume (~3–4 L), indicating the drug is almost entirely confined to the plasma compartment; at steady state, essentially all body drug is in the vascular space accessible to the dialyzer; despite high protein binding (limiting the instantaneous free fraction available for dialysis membrane crossing), the small Vd means dialysis progressively removes free drug, the protein-bound fraction rapidly re-equilibrates as free drug is removed, and total drug burden is continuously depleted; Drug A is therefore highly dialyzable. Drug B (Vd = 400 L) — at steady state, total body drug = Css × Vd = 10 mg/L × 400 L = 4,000 mg; amount in plasma = Css × Vplasma = 10 mg/L × 4 L = 40 mg; plasma drug as fraction of total = 40/4000 = 1% — only 1% of total body Drug B is in the plasma at any moment; dialysis can only access this 1%; even if all plasma drug is removed, 99% remains in peripheral tissues and immediately redistributes into plasma; Drug B is essentially non-dialyzable despite its favorable fu. Option B inverts the free drug formula (division instead of multiplication). Option C incorrectly states protein binding doesn't affect free concentration — it fundamentally does. Option D confuses bound and free fractions (pharmacologically active fraction is the free, unbound fraction). Option E correctly calculates free concentrations and Drug B's higher free concentration, but incorrectly states large Vd predicts dialyzability — it is the opposite; large Vd means most drug is in tissues, making dialysis ineffective.

3. A clinical pharmacology team investigates why two drugs — Drug X (pKa 9.2, basic amine, logP 3.1, MW 310 Da, fu 0.25, not a P-gp substrate) and Drug Y (pKa 4.8, weak acid, logP 2.4, MW 285 Da, fu 0.05, P-gp substrate) — have dramatically different CNS penetration despite similar molecular weights and lipophilicities. Drug X achieves a CSF:plasma ratio of 0.85, while Drug Y achieves a CSF:plasma ratio of 0.02. Using the physicochemical properties provided and the BBB penetration principles, explain the difference.

A) Drug X penetrates the CNS better than Drug Y primarily because of its higher molecular weight (310 vs 285 Da) — the BBB has size-selective pores that preferentially allow larger molecules to pass while excluding smaller molecules; Drug Y's lower MW is the dominant factor limiting its CNS penetration
B) Drug X has superior CNS penetration primarily because basic amines are actively transported across the BBB by a specific amine uptake transporter (NET/norepinephrine transporter) expressed on the luminal surface of BBB endothelial cells — all basic amine drugs with pKa > 8 use this transporter regardless of lipophilicity
C) The CSF:plasma ratio difference is explained by three converging factors: (1) Ionization at physiological pH — Drug X (pKa 9.2, basic amine): log([BH]/[B]) = pKa − pH = 9.2 − 7.4 = 1.8, so [BH]/[B] = 63:1 — Drug X is predominantly ionized (protonated) in plasma; however, the 1.6% unionized fraction (B form) is lipophilic (logP 3.1) and membrane-permeable; Drug Y (pKa 4.8, weak acid): log([A]/[HA]) = 7.4 − 4.8 = 2.6, so [A]/[HA] = 398:1 — Drug Y is even more extensively ionized at physiological pH, with only 0.25% in the unionized membrane-permeable form; (2) Free drug fraction — Drug X fu = 0.25 (25% free) versus Drug Y fu = 0.05 (5% free) — Drug X has 5-fold more free drug available for BBB crossing; (3) P-glycoprotein efflux — Drug Y is a P-gp substrate; even the small unionized fraction that diffuses into BBB endothelial cells is actively pumped back into the circulation by luminal P-gp, preventing CNS accumulation; Drug X is not a P-gp substrate and once it enters endothelial cells, it is not actively effluxed; all three factors combine to produce the 42-fold difference in CSF:plasma ratio
D) Drug X has better CNS penetration because its lower fu (0.25) means less plasma protein binding — lower protein binding always produces higher CNS penetration regardless of ionization state or P-gp status; Drug Y's higher fu (0.05) incorrectly written in the question should be 0.95 to explain poor CNS penetration
E) The CSF:plasma ratio difference is explained solely by the difference in logP — Drug X (logP 3.1) is more lipophilic than Drug Y (logP 2.4), and logP alone determines CNS penetration; ionization state and P-gp efflux are secondary factors that do not quantitatively explain the 42-fold difference in CSF:plasma ratio

ANSWER: C

Rationale:

This question requires simultaneous application of Henderson-Hasselbalch ionization calculations, free drug fraction concepts, and P-gp efflux pharmacokinetics to explain differential BBB penetration — demonstrating that CNS drug distribution is not determined by any single property but by the integrated product of multiple pharmacokinetic barriers. Three converging factors explain the 42-fold difference: (1) Ionization state analysis: Drug X (pKa 9.2, basic): at pH 7.4, [BH]/[B] = 10^(9.2−7.4) = 10^1.8 63; unionized fraction = 1/(1+63) = 1.56% — small but present; these molecules (logP 3.1) readily partition into the BBB lipid bilayer. Drug Y (pKa 4.8, weak acid): at pH 7.4, [A]/[HA] = 10^(7.4−4.8) = 10^2.6 398; unionized fraction = 1/(1+398) = 0.25% — 6-fold less unionized than Drug X, meaning less drug available for passive transcellular diffusion. (2) Free drug fraction: Drug X fu = 0.25 means 25% of plasma Drug X is unbound and available for BBB crossing; Drug Y fu = 0.05 means only 5% is free — 5-fold less available free drug. Combined ionization + protein binding effect: Drug X effective membrane-permeant fraction 0.0156 × 0.25 = 0.0039 (0.39% of total plasma Drug X); Drug Y effective membrane-permeant fraction 0.0025 × 0.05 = 0.000125 (0.0125% of total plasma Drug Y) — approximately 31-fold less for Drug Y before even considering P-gp. (3) P-gp efflux: Drug Y is additionally a P-gp substrate; P-gp on the luminal BBB surface actively effluxes Drug Y back into blood even after it has partitioned into the endothelial cell; this further reduces net CNS penetration by an additional factor of 2–10 depending on P-gp expression level. The combination of these three factors quantitatively explains the 42-fold difference in CSF:plasma ratios (Drug X: 0.85 vs Drug Y: 0.02). Option A is incorrect — MW difference of 25 Da is pharmacokinetically trivial; MW is not the primary determinant here. Option B is incorrect — NET is not a general BBB uptake transporter for all basic amine drugs; only specific neurotransmitter transporters (DAT, NET, SERT) mediate active uptake of specific substrates. Option D inverts the Drug X and Drug Y fu values and contains the incorrect premise that lower fu means less protein binding. Option E is incorrect — while logP difference contributes, it alone cannot explain a 42-fold ratio difference between drugs with logP values of 3.1 and 2.4 (a relatively modest difference).

4. A 45-year-old woman with rheumatoid arthritis on methotrexate 15 mg weekly is found to have an albumin of 21 g/L (normal 35–50 g/L) due to malnutrition. Methotrexate is approximately 50% albumin-bound (fu = 0.50 normally). Assuming that at severely reduced albumin, methotrexate's fu increases to 0.80 (80% free), predict the pharmacokinetic consequences of hypoalbuminemia on methotrexate distribution and toxicity, and explain why simply measuring total plasma methotrexate concentration may be misleading in this patient.

A) Hypoalbuminemia increases methotrexate fu from 0.50 to 0.80 — the free methotrexate concentration increases; since methotrexate's mechanism depends on intracellular DHFR inhibition and free drug crosses cell membranes, greater free drug concentration increases both antiproliferative efficacy and toxicity (myelosuppression, mucositis, hepatotoxicity); total plasma concentration measurement captures both bound and free methotrexate — in the hypoalbuminemic patient, the same total plasma concentration as a normoalbuminemic patient represents a much higher free (pharmacologically active) concentration; relying on total concentration alone to guide methotrexate dosing in this patient risks underestimating actual drug exposure and toxicity risk; free methotrexate concentration measurement or dose reduction should be considered
B) Hypoalbuminemia has no effect on methotrexate pharmacokinetics — methotrexate is a hydrophilic drug that distributes in total body water; its pharmacokinetics depend solely on renal clearance, which is unrelated to albumin concentration; total plasma methotrexate concentration measurement is adequate regardless of albumin levels
C) Hypoalbuminemia reduces total plasma methotrexate concentration because less drug is bound to albumin, causing a reduction in the total measured concentration; the unbound fraction is unchanged; to maintain therapeutic methotrexate levels in hypoalbuminemic patients, the dose should be increased proportionally to the albumin deficit
D) Hypoalbuminemia reduces methotrexate Vd because less drug is retained in the plasma compartment — with reduced albumin binding, methotrexate distributes more into peripheral tissues, producing a paradoxical reduction in plasma concentration despite unchanged dosing; this distribution effect produces therapeutic failure requiring dose escalation
E) Hypoalbuminemia causes methotrexate toxicity exclusively through a pharmacodynamic mechanism — reduced albumin activates hepatic stellate cells that sensitize the liver to methotrexate-induced fibrosis; the protein binding change is pharmacokinetically negligible compared to this albumin-mediated pharmacodynamic sensitization

ANSWER: A

Rationale:

This question explores the pharmacokinetic and clinical consequences of protein binding changes from hypoalbuminemia — and why total plasma drug concentration measurements can be dangerously misleading when protein binding is altered. Normally, methotrexate is 50% albumin-bound, meaning fu = 0.50 and Cfree = 0.50 × Ctotal. In severe hypoalbuminemia (albumin 21 g/L), binding sites are reduced and fu increases to 0.80: Cfree = 0.80 × Ctotal. At the same total plasma methotrexate concentration (say, 0.1 µmol/L): Normal albumin: Cfree = 0.50 × 0.1 = 0.05 µmol/L. Hypoalbuminemia: Cfree = 0.80 × 0.1 = 0.08 µmol/L — 60% higher free drug at identical total concentration. Methotrexate exerts its pharmacological and toxic effects as free drug — it crosses cell membranes to inhibit intracellular dihydrofolate reductase (DHFR) and thymidylate synthase. Higher free methotrexate: (1) Produces greater intracellular drug accumulation in rapidly dividing cells (bone marrow, GI mucosa) — increasing myelosuppression and mucositis risk; (2) Distributes more readily into tissues, increasing hepatic methotrexate concentrations (hepatotoxicity risk); (3) Undergoes greater renal filtration (only free drug is filtered at the glomerulus) — potentially increasing renal clearance of methotrexate, which could paradoxically reduce total plasma concentration while free drug concentrations remain elevated. When a clinician measures total plasma methotrexate and finds it "within range" in this hypoalbuminemic patient, they may not recognize that the free drug concentration is significantly higher — leading to underestimation of toxicity risk. In clinical practice, hypoalbuminemia is a recognized risk factor for methotrexate toxicity; some guidelines recommend dose reduction in patients with significant hypoalbuminemia. This same principle applies to phenytoin (fu normally 0.10, increases to 0.20–0.30 in hypoalbuminemia or CKD — "normal" total phenytoin levels may mask sub-therapeutic free phenytoin; conversely, "normal" total levels with elevated fu may represent toxic free drug concentrations). Option B is incorrect — while methotrexate is hydrophilic, albumin binding significantly affects its free concentration and clinical activity; protein binding changes are pharmacokinetically consequential for methotrexate. Option C is incorrect — hypoalbuminemia increases free methotrexate and may actually increase renal clearance (free drug filtered), but the dominant clinical concern is increased free drug concentration, not decreased total concentration requiring dose escalation. Option D incorrectly attributes reduced plasma concentration to increased tissue distribution — the mechanism described (hypoalbuminemia reducing Vd) is the opposite of reality; reduced protein binding typically increases Vd as more free drug distributes into tissues. Option E is a pharmacodynamic fabrication — hepatic stellate cell activation by albumin is not a recognized pharmacological mechanism of methotrexate toxicity.

5. A 32-year-old man is admitted to the ICU following a tricyclic antidepressant (TCA) overdose. He ingested amitriptyline, which has the following pharmacokinetic properties: Vd approximately 18 L/kg (1260 L in a 70 kg adult), plasma protein binding 95% (primarily albumin and AGP), pKa 9.4 (basic amine), logP 4.9, elimination half-life approximately 20–40 hours. His serum amitriptyline level is reported as 800 ng/mL (toxic). The ICU team considers hemodialysis. A clinical pharmacologist advises against dialysis for amitriptyline removal. Which of the following best provides the pharmacokinetic basis for this recommendation, and identifies the correct management approach?

A) Hemodialysis is ineffective for amitriptyline removal because the drug is metabolized by CYP2D6 — dialysis only removes renally eliminated drugs; since amitriptyline is hepatically eliminated, dialysis has no mechanism of action for its removal; activated charcoal administered within 1 hour of ingestion is the correct approach
B) Hemodialysis is contraindicated for amitriptyline toxicity due to the heparin anticoagulation required for the dialysis circuit — heparin can precipitate cardiac arrhythmias through anti-thrombin effects that compound amitriptyline-induced QRS prolongation; alkaline hemofiltration without anticoagulation is the pharmacokinetically appropriate alternative
C) Hemodialysis will not effectively remove amitriptyline because its Vd of approximately 1260 L means that at steady state, the plasma contains only a tiny fraction of total body amitriptyline — with plasma volume of approximately 4 L, plasma drug = Css × Vplasma = 800 ng/mL × 4000 mL = 3,200,000 ng = 3.2 mg; total body drug = Css × Vd = 800 ng/mL × 1,260,000 mL = 1,008,000,000 ng = 1008 mg; plasma drug represents only 0.3% of total body drug; even if dialysis removed 100% of plasma amitriptyline, 99.7% of drug would remain in tissues and rapidly redistribute into plasma — making dialysis pharmacokinetically futile; management focuses on supportive care (airway, IV sodium bicarbonate for QRS widening, benzodiazepines for seizures, lipid emulsion therapy for refractory toxicity)
D) Hemodialysis is effective for amitriptyline removal because its low fu (0.05 free fraction) ensures that free drug crosses the dialysis membrane rapidly — TCA overdoses are best managed with aggressive high-flux hemodialysis over 4–6 hours; the plasma level of 800 ng/mL confirms systemic distribution that dialysis can access
E) Hemodialysis should be initiated immediately because amitriptyline's pKa of 9.4 means it is predominantly unionized in plasma (pH 7.4) — unionized drugs cross dialysis membranes most readily; alkaline dialysate (pH 8.5) further increases the unionized fraction in the dialysate compartment, creating a favorable ionization gradient for drug removal

ANSWER: C

Rationale:

This case illustrates the quantitative pharmacokinetic basis for why hemodialysis is ineffective for TCA overdose — one of the most important applications of Vd in clinical toxicology. The mathematical calculation makes the argument incontrovertibly clear. At a measured plasma amitriptyline concentration of 800 ng/mL = 800 ng/mL = 0.8 mcg/mL: Amount in plasma = Css × Vplasma = 0.8 mcg/mL × 4,000 mL = 3,200 mcg = 3.2 mg. Total body drug = Css × Vd = 0.8 mcg/mL × 1,260,000 mL = 1,008,000 mcg 1,008 mg. Fraction of drug in plasma = 3.2/1008 = 0.003 = 0.3%. This means 99.7% of amitriptyline is sequestered in peripheral tissues (bound to tissue proteins, accumulated in intracellular compartments). If a dialyzer were to achieve 100% plasma drug extraction (which is physically impossible but represents the theoretical maximum), only 3.2 mg of the approximately 1,008 mg total body burden would be removed — 0.3% of total drug. As soon as plasma concentrations fall, tissue drug rapidly redistributes into plasma, restoring the plasma concentration toward baseline. Dialysis cannot meaningfully deplete the tissue compartment because blood flow through the dialyzer (200–400 mL/min) is too slow to exhaust the enormous tissue reservoir. The same argument applies to all drugs with Vd > 2–5 L/kg: digoxin (~7 L/kg), chloroquine (~300 L/kg), TCAs (~18 L/kg), phenothiazines (~20 L/kg). Correct management of TCA overdose: airway protection (TCAs cause seizures, QRS prolongation causing ventricular arrhythmia, hypotension); IV sodium bicarbonate (raises serum pH to ~7.50–7.55, increasing ionization of amitriptyline in plasma and reducing tissue distribution through pH-mediated ion trapping, directly treating QRS widening through sodium loading); benzodiazepines for seizures; IV lipid emulsion for refractory toxicity (lipid sink theory — TCA partitions into lipid emulsion out of tissue). Option A is incorrect — the reasoning about hepatic elimination is true (TCAs are hepatically metabolized) but the explanation for dialysis failure given in the question is the Vd, not the elimination route; activated charcoal is appropriate if given early (<1–2 hours). Option B is a fabricated pharmacological claim — heparin does not cause cardiac arrhythmias through anti-thrombin mechanisms interacting with TCA QRS widening. Option D inverts the clinical pharmacological reasoning — low fu would if anything make dialysis less effective (less free drug crossing the membrane), and the premise that dialysis is effective contradicts the quantitative calculation. Option E is incorrect — amitriptyline (pKa 9.4) is predominantly ionized (protonated) in plasma (pH 7.4), not unionized; the ionized form crosses dialysis membranes less readily; alkaline dialysate would increase unionized fraction in dialysate (reducing the gradient for drug extraction), not increase removal efficiency.

6. Propofol is an IV anesthetic agent with the following pharmacokinetic profile: logP 3.79, 98% plasma protein binding (albumin), Vd approximately 60 L/kg (4200 L in a 70 kg adult), elimination half-life approximately 0.5–1.5 hours (terminal half-life 4–7 hours due to two-compartment distribution), onset within 30–40 seconds of IV bolus, and clinical duration of 5–8 minutes for a single bolus. A patient receives a 2 mg/kg propofol bolus IV for procedural sedation, followed by a two-hour continuous infusion at 4 mg/kg/hour for maintenance. At the end of the infusion, predict the pharmacokinetic behavior of propofol plasma concentrations and clinical recovery time compared to the single bolus scenario, explaining the pharmacokinetic principle responsible.

A) Recovery time after the two-hour infusion will be identical to recovery after a single bolus — propofol's short elimination half-life of 0.5–1.5 hours ensures that regardless of infusion duration, all drug is eliminated within one to two half-lives of the infusion ending; infusion duration does not affect recovery time for drugs with short half-lives
B) Recovery time after a two-hour infusion will be substantially longer than after a single bolus — during a two-hour infusion at 4 mg/kg/hour, propofol saturates both the central compartment and progressively fills the enormous peripheral compartment (Vd ~60 L/kg); when the infusion stops, propofol plasma concentrations fall as both elimination occurs and remaining drug in the central compartment redistributes into peripheral tissues; however, the peripheral compartment (muscle, adipose) continues to return drug to plasma over hours (retardation of the concentration-time curve by redistribution back from peripheral tissues); the time for plasma concentration to fall 50% below the infusion steady-state level increases with infusion duration — this is the context-sensitive half-time concept: for propofol after a 2-hour infusion, context-sensitive half-time is approximately 10–40 minutes (still relatively short for propofol due to high hepatic clearance); however, after very prolonged infusions (>8–10 hours), adipose tissue (which equilibrates slowly with plasma due to poor perfusion) begins contributing to redistribution back into plasma, further extending recovery; the clinical implication is that cumulative drug loading in peripheral compartments increases with infusion duration, eventually making recovery time infusion-duration-dependent
C) Recovery time after a two-hour infusion will be shorter than after a single bolus — continuous infusion maintains steady plasma concentrations that prevent receptor upregulation and tolerance, allowing lower total drug exposure than repeated boluses; receptor sensitivity is preserved and recovery is faster due to maintained inhibitory tone preventing compensatory excitatory response
D) The two-compartment model predicts that recovery after any infusion of propofol is exclusively determined by its elimination half-life of 0.5–1.5 hours — the peripheral compartment only affects the alpha (distribution) phase immediately after bolus injection and has no relevance to recovery after continuous infusion because steady-state equilibrium between compartments is achieved during infusion
E) Recovery time is determined solely by the infusion rate — higher infusion rates require longer recovery because more drug is administered per unit time; the Vd and two-compartment kinetics are irrelevant to recovery time prediction after continuous infusion in clinical practice

ANSWER: B

Rationale:

This question introduces the context-sensitive half-time concept — one of the most clinically important pharmacokinetic principles in anesthesiology and critical care pharmacology, and a direct consequence of two-compartment (or multi-compartment) drug distribution. After a single IV bolus of propofol, rapid redistribution from the central compartment (brain, heart, liver — highly perfused) to peripheral compartments (muscle) terminates the anesthetic effect within 5–8 minutes — the thiopental/propofol redistribution paradigm. This rapid initial offset occurs even though elimination half-life is 0.5–1.5 hours, because redistribution (not elimination) governs the early concentration fall. Context-sensitive half-time (CSHT) is defined as the time for plasma drug concentration to decrease by 50% after stopping a continuous infusion of a specified duration. For propofol, the CSHT is relatively short (approximately 10–40 minutes after 2 hours of infusion, increasing to approximately 60 minutes after 8 hours) because propofol has high hepatic clearance (~30 mL/kg/min — nearly equal to hepatic blood flow, making it a high-extraction drug) that rapidly eliminates drug from plasma. Nevertheless, during a 2-hour infusion, propofol progressively fills muscle (peripheral compartment 1) and begins entering adipose tissue (peripheral compartment 2, which is large but poorly perfused). When the infusion stops, peripheral compartment drug continues to redistribute back into plasma, retarding the plasma concentration decline below what simple elimination alone would predict. The critical clinical implication is that propofol's recovery profile changes with infusion duration — short (<2 hours) infusions have CSHT dominated by redistribution and fast recovery; prolonged infusions (>6–8 hours, particularly in ICU sedation) have increasing CSHT as adipose tissue accumulation creates a slowly releasing depot; after very prolonged infusions (days), propofol infusion syndrome (PRIS) risk also increases. Option A is incorrect — the short elimination half-life is not the sole determinant; redistribution from peripheral compartments extends recovery beyond what elimination alone predicts; CSHT increases with infusion duration for multi-compartment drugs. Option C is incorrect — receptor upregulation after infusion is not the mechanism; recovery time extends, not shortens, with longer infusions. Option D is incorrect — the peripheral compartment remains pharmacokinetically relevant after continuous infusion ends; redistribution from peripheral back to central compartment retards plasma concentration decline. Option E is incorrect — Vd and compartmental kinetics are the primary pharmacokinetic determinants of recovery time after infusion; infusion rate determines steady-state concentration but not the rate of concentration decline after stopping.

7. A 24-year-old woman at 32 weeks gestation presents to the emergency department with a tonic-clonic seizure. She is given IV magnesium sulfate per eclampsia protocol. The decision is made to administer a loading dose of lorazepam if seizures persist. Lorazepam crosses the placenta readily and distributes into fetal tissues. The neonatology team is placed on standby. Using placental transfer pharmacokinetics, predict the fetal effects most likely to be observed and identify the pharmacokinetic property of lorazepam that determines the rate and extent of placental transfer.

A) Lorazepam will not reach the fetus in pharmacologically significant concentrations because P-glycoprotein at the placenta actively effluxes all benzodiazepines back into the maternal circulation — the fetal CNS is completely protected from maternally administered lorazepam; neonatology standby is unnecessary
B) Lorazepam's placental transfer is determined primarily by its molecular weight (321 Da) — since it exceeds the 200 Da threshold for aqueous pore diffusion, it can only cross the placenta through specific benzodiazepine receptor-mediated transcytosis; this slow, receptor-mediated mechanism limits fetal exposure to pharmacologically subtherapeutic concentrations
C) Lorazepam (MW 321 Da, logP 2.4, fu approximately 0.10, pKa 1.3 — essentially completely unionized at physiological pH 7.4) has physicochemical properties conducive to rapid placental transfer by passive transcellular diffusion — low MW, moderate lipophilicity, essentially completely unionized at physiological pH, and moderate protein binding (10% free drug available for transfer); once in fetal circulation, lorazepam distributes into fetal CNS and binds GABA-A receptors; the neonatal CNS is particularly sensitive to GABA-A potentiation due to immature receptor composition and blood-brain barrier permeability; expected neonatal effects after maternal lorazepam include respiratory depression, hypotonia ("floppy infant" syndrome), hypothermia, and prolonged sedation — requiring neonatal resuscitation preparedness including flumazenil (if needed) and respiratory support
D) Placental transfer of lorazepam is primarily governed by its plasma protein binding — lorazepam is 90% albumin-bound, meaning only 10% (fu = 0.10) is available for placental transfer; this degree of protein binding completely prevents fetal drug exposure because bound drug cannot cross biological membranes; no neonatal effects are expected
E) Lorazepam crosses the placenta by active transport via OAT2 (organic anion transporter 2), which is expressed on the maternal-facing surface of syncytiotrophoblasts — this carrier-mediated mechanism is saturable and therefore at maternal therapeutic plasma concentrations, placental transfer is minimal; neonatal effects only occur at maternal overdose concentrations that saturate OAT2

ANSWER: C

Rationale:

This case applies placental pharmacokinetics to a critical obstetric emergency scenario. Lorazepam's physicochemical properties predict efficient placental transfer: (1) MW 321 Da — below the approximate 500 Da threshold for meaningful restriction of passive diffusion across biological membranes; (2) logP 2.4 — moderate lipophilicity suitable for transcellular membrane partitioning; (3) pKa 1.3 — a weak acid with pKa well below physiological pH 7.4; log([A]/[HA]) = 7.4 − 1.3 = 6.1, so [A]/[HA] = 10^6.1 1,260,000:1 — essentially completely ionized at physiological pH; however, for drugs with very low pKa, the Henderson-Hasselbalch equation applies, but the practical consequence is that lorazepam at physiological pH exists almost entirely as its ionized carboxylate form; this might appear to limit membrane crossing, but clinical experience and pharmacokinetic studies confirm rapid placental transfer — the ionized form at the physiological pH range still crosses effectively through the hydrophilic regions, and the small unionized fraction has excellent membrane permeability; (4) fu 0.10 — with 90% plasma protein binding, 10% is free for placental transfer; this is sufficient for significant fetal exposure given the large concentration gradient from maternal to fetal circulation. Clinical consequences of fetal lorazepam exposure: neonates have immature GABA-A receptor subunit composition (more alpha-2/alpha-3 subunits, which produce stronger sedation and less anxiolysis than adult alpha-1 predominance); immature BBB allows greater CNS drug penetration; immature hepatic glucuronidation (UGT2B7 — the primary lorazepam elimination pathway) prolongs drug half-life; immature respiratory drive is particularly sensitive to GABA-A potentiation. The neonatal syndrome: "floppy baby" (hypotonia from muscle relaxation), respiratory depression (central apnea), hypothermia, and prolonged sedation lasting hours to days. Neonatal resuscitation preparedness is essential. Option A is incorrect — while P-gp is expressed at the placenta (providing partial protection), lorazepam crosses the placenta readily as confirmed by clinical experience; placental P-gp does not completely prevent fetal exposure for most lipophilic drugs. Option B is incorrect — the 200 Da threshold for aqueous pore diffusion is not the relevant barrier; lorazepam at 321 Da crosses primarily by transcellular diffusion, not pore diffusion; benzodiazepine receptor-mediated transcytosis is not a recognized placental transport mechanism. Option D is incorrect — protein binding reduces (does not completely prevent) the rate of placental transfer; free drug (fu = 0.10) is available for diffusion, and continuous drug transfer occurs as protein-bound drug equilibrates with free drug as concentrations adjust. Option E is incorrect — lorazepam is a weak acid and would not be a substrate of OAT2 (which transports organic anions, but lorazepam's transfer is primarily by passive diffusion, not active transport); no evidence supports OAT2-mediated placental lorazepam transfer.

8. A neurologist is selecting an antibiotic for treatment of bacterial meningitis caused by Listeria monocytogenes in a 68-year-old immunocompromised patient. Two options are available: ampicillin (a beta-lactam antibiotic) and chloramphenicol. Using BBB penetration pharmacokinetics, compare the expected CSF penetration of these two drugs and explain which is pharmacokinetically superior for CNS Listeria infection treatment.

A) Ampicillin is pharmacokinetically superior to chloramphenicol for CNS Listeria treatment because ampicillin's high molecular weight and hydrophilicity ensure it concentrates preferentially in the CSF through active transport by the choroid plexus OAT1 transporter; chloramphenicol's lipophilicity prevents CSF penetration because lipophilic drugs are excluded from the hydrophilic CSF compartment by the choroid plexus epithelium
B) Chloramphenicol has superior CNS penetration compared to ampicillin based on their pharmacokinetic profiles: chloramphenicol (MW 323 Da, logP 1.14, low protein binding ~53%, not a P-gp substrate, predominantly unionized at physiological pH) readily crosses the intact BBB by passive transcellular diffusion, achieving CSF concentrations approaching 30–50% of plasma (and higher in inflamed meninges); ampicillin (MW 349 Da, logP −1.35 — highly hydrophilic, high ionization at pH 7.4, not lipophilic, not a P-gp substrate) crosses the intact BBB very poorly by passive diffusion because its negative logP indicates it partitions strongly toward the aqueous phase rather than the lipid bilayer; ampicillin achieves CSF:plasma ratios of only 1–2% with intact meninges (rising to 5–20% with inflamed meninges due to disruption of BBB tight junctions); however, despite poor BBB penetration, ampicillin remains the first-line treatment for CNS Listeria because it achieves bactericidal concentrations in inflamed meninges sufficient for clinical efficacy, while chloramphenicol is bacteriostatic against Listeria (not bactericidal) — illustrating that pharmacokinetic superiority of CNS penetration does not automatically translate to superior clinical outcome if the pharmacodynamic profile is inadequate
C) Both ampicillin and chloramphenicol achieve identical CSF concentrations (CSF:plasma ratio = 1.0) in meningitis because meningeal inflammation completely disrupts the BBB, making all drugs equally CNS-penetrant regardless of their physicochemical properties; antibiotic selection should be based on spectrum of activity alone
D) Chloramphenicol is both pharmacokinetically and pharmacodynamically superior to ampicillin for CNS Listeria infection — chloramphenicol's better BBB penetration combines with its bactericidal activity against Listeria to make it the preferred agent; ampicillin's poor CSF penetration means it cannot achieve effective concentrations even in inflamed meninges
E) Ampicillin's CSF penetration is equivalent to chloramphenicol because all beta-lactam antibiotics have been engineered to express a specific BBB uptake transporter (PEPT2/SLC15A2) substrate sequence that actively concentrates them in the CSF; this active transport compensates completely for their poor passive permeability

ANSWER: B

Rationale:

This question applies BBB pharmacokinetic principles to an antibiotic selection scenario while adding the crucial pharmacodynamic dimension — illustrating that optimal prescribing requires integrating both pharmacokinetic and pharmacodynamic reasoning simultaneously. BBB penetration comparison: Chloramphenicol (MW 323 Da, logP 1.14 — lipophilic, uncharged chlorinated aromatic compound, low protein binding ~53%, essentially un-ionized at physiological pH as a neutral molecule): these properties are close to optimal for passive transcellular BBB diffusion — moderate MW, positive logP, predominantly non-ionized, moderate protein binding; chloramphenicol achieves CSF:plasma ratios of 30–80% (one of the highest of any antibiotic), penetrating both the intact and inflamed BBB effectively. Ampicillin (MW 349 Da, logP −1.35 — highly hydrophilic, negative logP indicates aqueous preference, amphoteric molecule with multiple ionizable groups — amino group pKa ~7.3, carboxylic acid pKa ~2.5 — predominantly ionized at physiological pH, 15–25% protein bound): the combination of negative logP and extensive ionization makes ampicillin essentially unable to passively diffuse across the intact lipid bilayer BBB; CSF:plasma ratio is approximately 1–2% with intact meninges, rising to 5–20% with inflamed meninges as tight junctions are disrupted and paracellular permeability increases. Despite these pharmacokinetic differences, the treatment outcome reality is pharmacodynamically determined: ampicillin is bactericidal against Listeria monocytogenes — it kills the organism, which is required for clinical cure in CNS infection in an immunocompromised host. Chloramphenicol is only bacteriostatic against Listeria — it inhibits protein synthesis and suppresses bacterial growth but cannot kill organisms; in immunocompromised patients without intact bactericidal immune function, bacteriostatic activity alone is insufficient for cure. The superior CNS pharmacokinetics of chloramphenicol cannot overcome its pharmacodynamic limitation of bacteriostatic (not bactericidal) activity. This integration of pharmacokinetics and pharmacodynamics is the core of rational CNS anti-infective therapy selection. Option A is incorrect — ampicillin's hydrophilicity does not produce preferential CSF concentration; OAT1 is a renal transporter, not a primary CNS drug uptake mechanism for ampicillin; and chloramphenicol's lipophilicity facilitates, not prevents, CNS penetration. Option C is incorrect — while meningeal inflammation increases drug penetration for many drugs, the quantitative increase is drug-specific and depends on baseline physicochemical properties; chloramphenicol and ampicillin do not achieve identical CSF concentrations even with inflamed meninges. Option D incorrectly classifies chloramphenicol as bactericidal against Listeria — it is bacteriostatic; ampicillin, though having poorer CNS penetration, is preferred because of its bactericidal activity. Option E is incorrect — beta-lactam antibiotics are not substrates of PEPT2 in a way that produces equivalent CNS concentrations to chloramphenicol; PEPT2 is expressed at the choroid plexus and provides some contribution to CSF concentrations of beta-lactams but does not compensate for their markedly inferior passive BBB permeability.